Lisanti Capital Growth LLC cut its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 25.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 175,470 shares of the biotechnology company's stock after selling 59,565 shares during the period. Lisanti Capital Growth LLC owned about 0.07% of ADMA Biologics worth $3,009,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the stock. State Street Corp grew its holdings in ADMA Biologics by 61.4% during the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company's stock worth $259,970,000 after acquiring an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC grew its holdings in ADMA Biologics by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company's stock worth $107,606,000 after acquiring an additional 137,989 shares in the last quarter. Perpetual Ltd bought a new position in ADMA Biologics during the 4th quarter worth about $62,300,000. Lord Abbett & CO. LLC bought a new position in ADMA Biologics during the 3rd quarter worth about $61,858,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after acquiring an additional 2,613,482 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.
Several research analysts have issued reports on ADMA shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday. Raymond James increased their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th. Finally, HC Wainwright increased their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th.
Read Our Latest Stock Analysis on ADMA
ADMA stock opened at $16.91 on Friday. The firm has a market cap of $4.00 billion, a price-to-earnings ratio of 60.39 and a beta of 0.75. The firm has a 50-day simple moving average of $16.67 and a two-hundred day simple moving average of $17.96. ADMA Biologics, Inc. has a one year low of $5.88 and a one year high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.